Compare Natco Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ABBOTT INDIA NATCO PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 15.5 44.7 34.7% View Chart
P/BV x 3.1 12.8 23.8% View Chart
Dividend Yield % 1.5 0.5 270.9%  

Financials

 NATCO PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
ABBOTT INDIA
Mar-18
NATCO PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,0806,110 17.7%   
Low Rs6713,996 16.8%   
Sales per share (Unadj.) Rs592.11,552.2 38.1%  
Earnings per share (Unadj.) Rs188.4188.8 99.8%  
Cash flow per share (Unadj.) Rs206.3196.4 105.0%  
Dividends per share (Unadj.) Rs8.2555.00 15.0%  
Dividend yield (eoy) %0.91.1 86.6%  
Book value per share (Unadj.) Rs833.6796.6 104.6%  
Shares outstanding (eoy) m36.9021.25 173.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.53.3 45.4%   
Avg P/E ratio x4.626.8 17.4%  
P/CF ratio (eoy) x4.225.7 16.5%  
Price / Book Value ratio x1.16.3 16.6%  
Dividend payout %4.429.1 15.0%   
Avg Mkt Cap Rs m32,311107,376 30.1%   
No. of employees `0004.83.3 145.4%   
Total wages/salary Rs m3,2563,937 82.7%   
Avg. sales/employee Rs Th4,522.59,929.3 45.5%   
Avg. wages/employee Rs Th674.01,185.1 56.9%   
Avg. net profit/employee Rs Th1,439.01,207.7 119.2%   
INCOME DATA
Net Sales Rs m21,84832,985 66.2%  
Other income Rs m4041,170 34.5%   
Total revenues Rs m22,25234,155 65.2%   
Gross profit Rs m9,2845,245 177.0%  
Depreciation Rs m662162 408.9%   
Interest Rs m15438 403.1%   
Profit before tax Rs m8,8726,215 142.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9202,203 87.2%   
Profit after tax Rs m6,9524,012 173.3%  
Gross profit margin %42.515.9 267.2%  
Effective tax rate %21.635.4 61.1%   
Net profit margin %31.812.2 261.6%  
BALANCE SHEET DATA
Current assets Rs m21,30722,655 94.1%   
Current liabilities Rs m5,9206,681 88.6%   
Net working cap to sales %70.448.4 145.4%  
Current ratio x3.63.4 106.1%  
Inventory Days Days7365 113.1%  
Debtors Days Days10729 365.3%  
Net fixed assets Rs m14,986835 1,793.7%   
Share capital Rs m369213 173.6%   
"Free" reserves Rs m30,35316,715 181.6%   
Net worth Rs m30,76016,928 181.7%   
Long term debt Rs m00-   
Total assets Rs m37,15124,162 153.8%  
Interest coverage x58.6163.7 35.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.61.4 43.1%   
Return on assets %19.116.8 114.1%  
Return on equity %22.623.7 95.4%  
Return on capital %29.336.9 79.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,322369 2,800.7%   
Fx outflow Rs m2,9783,807 78.2%   
Net fx Rs m7,343-3,438 -213.6%   
CASH FLOW
From Operations Rs m4,6361,527 303.6%  
From Investments Rs m-11,155-2,148 519.2%  
From Financial Activity Rs m6,509-1,024 -635.5%  
Net Cashflow Rs m-18-1,646 1.1%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 7.9 99.2%  
FIIs % 16.6 0.1 16,630.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.1 152.0%  
Shareholders   25,395 18,270 139.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SANOFI INDIA  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS